Gary Hoel

704 total citations
19 papers, 518 citations indexed

About

Gary Hoel is a scholar working on Urology, Rheumatology and Endocrinology, Diabetes and Metabolism. According to data from OpenAlex, Gary Hoel has authored 19 papers receiving a total of 518 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Urology, 9 papers in Rheumatology and 6 papers in Endocrinology, Diabetes and Metabolism. Recurrent topics in Gary Hoel's work include Urinary Bladder and Prostate Research (16 papers), Pelvic floor disorders treatments (9 papers) and Hormonal and reproductive studies (6 papers). Gary Hoel is often cited by papers focused on Urinary Bladder and Prostate Research (16 papers), Pelvic floor disorders treatments (9 papers) and Hormonal and reproductive studies (6 papers). Gary Hoel collaborates with scholars based in United States and Canada. Gary Hoel's co-authors include Lawrence A. Hill, Weining Volinn, Leonard S. Marks, Marc Gittelman, Heather Thomas, Kim E. Caramelli, Scott MacDiarmid, Peter K. Sand, Roger R. Dmochowski and Herbert Lepor and has published in prestigious journals such as American Journal of Obstetrics and Gynecology, The Journal of Urology and Clinical Pharmacology & Therapeutics.

In The Last Decade

Gary Hoel

19 papers receiving 497 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Gary Hoel United States	10	471	265	152	141	114	19	518
David Mitcheson United States	7	610 1.3×	468 1.8×	71 0.5×	70 0.5×	364 3.2×	10	668
M. Wooning Netherlands	7	462 1.0×	340 1.3×	54 0.4×	31 0.2×	258 2.3×	8	499
Reiner Tretter Netherlands	10	242 0.5×	198 0.7×	42 0.3×	17 0.1×	154 1.4×	13	333
Yoshitaka Tomiyama Japan	15	317 0.7×	43 0.2×	77 0.5×	234 1.7×	21 0.2×	30	472
Sara Y. Gao United States	6	294 0.6×	176 0.7×	15 0.1×	50 0.4×	134 1.2×	11	350
Daniel I. Gup United States	8	279 0.6×	35 0.1×	172 1.1×	128 0.9×	18 0.2×	8	345
Çağrı Akın Şekerci Türkiye	10	148 0.3×	99 0.4×	16 0.1×	38 0.3×	31 0.3×	52	280
D. Kröpfl Germany	9	142 0.3×	53 0.2×	43 0.3×	63 0.4×	15 0.1×	29	273
Salvatore Cascio Ireland	14	267 0.6×	43 0.2×	15 0.1×	59 0.4×	69 0.6×	36	430
C. Vlachopoulos Greece	7	56 0.1×	20 0.1×	138 0.9×	68 0.5×	23 0.2×	23	381

Countries citing papers authored by Gary Hoel

Since Specialization

Citations

This map shows the geographic impact of Gary Hoel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gary Hoel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gary Hoel more than expected).

Fields of papers citing papers by Gary Hoel

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gary Hoel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gary Hoel. The network helps show where Gary Hoel may publish in the future.

Co-authorship network of co-authors of Gary Hoel

This figure shows the co-authorship network connecting the top 25 collaborators of Gary Hoel. A scholar is included among the top collaborators of Gary Hoel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gary Hoel. Gary Hoel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

Marks, Leonard S., Marc Gittelman, Lawrence A. Hill, Weining Volinn, & Gary Hoel. (2012). Rapid Efficacy of the Highly Selective α_1A-Adrenoceptor Antagonist Silodosin in Men With Signs and Symptoms of Benign Prostatic Hyperplasia: Pooled Results of 2 Phase 3 Studies. The Journal of Urology. 189(1S). S122–8. 92 indexed citations

Sand, Peter K., et al.. (2011). Effect of baseline symptom severity on continence improvement mediated by oxybutynin chloride topical gel. Research and Reports in Urology. Volume 3. 145–150. 1 indexed citations

Sand, Peter K., et al.. (2011). Effect of baseline symptom severity on continence improvement mediated by oxybutynin chloride topical gel. Europe PMC (PubMed Central). 145–145. 3 indexed citations

Dmochowski, Roger R., Diane K. Newman, Peter K. Sand, et al.. (2011). Pharmacokinetics of Oxybutynin Chloride Topical Gel. Clinical Drug Investigation. 31(8). 559–571. 12 indexed citations

Sand, Peter K., G. Willy Davila, Vincent Lucente, et al.. (2011). Efficacy and safety of oxybutynin chloride topical gel for women with overactive bladder syndrome. American Journal of Obstetrics and Gynecology. 206(2). 168.e1–168.e6. 16 indexed citations

Nickel, J. Curtis, Michael P. O’Leary, Herbert Lepor, et al.. (2011). 1433 EFFECTS OF SILODOSIN IN MEN WITH MODERATE OR SEVERE CHRONIC PROSTATITIS/CHRONIC PELVIC PAIN SYNDROME: A DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STUDY. The Journal of Urology. 185(4S). 2 indexed citations

Nickel, J. Curtis, Michael P. O’Leary, Herbert Lepor, et al.. (2011). Silodosin for Men With Chronic Prostatitis/Chronic Pelvic Pain Syndrome: Results of a Phase II Multicenter, Double-Blind, Placebo Controlled Study. The Journal of Urology. 186(1). 125–131. 59 indexed citations

MacDiarmid, Scott, Lawrence A. Hill, Weining Volinn, & Gary Hoel. (2010). Lack of Pharmacodynamic Interaction of Silodosin, a Highly Selective α1a-Adrenoceptor Antagonist, With the Phosphodiesterase-5 Inhibitors Sildenafil and Tadalafil in Healthy Men. Urology. 75(3). 520–525. 26 indexed citations

Morganroth, Joel, Herbert Lepor, Lawrence A. Hill, Weining Volinn, & Gary Hoel. (2010). Effects of the Selective α1A-Adrenoceptor Antagonist Silodosin on ECGs of Healthy Men in a Randomized, Double-Blind, Placebo- and Moxifloxacin-Controlled Study. Clinical Pharmacology & Therapeutics. 87(5). 609–613. 19 indexed citations

10.

Marks, Leonard S., et al.. (2010). Effect of silodosin on specific urinary symptoms associated with benign prostatic hyperplasia: analysis of international prostate symptom scores in 2 phase III clinical studies. PubMed. 3. 1–1. 3 indexed citations

11.

Gittelman, Marc, Leonard S. Marks, Lawrence A. Hill, Weining Volinn, & Gary Hoel. (2010). Effect of silodosin on specific urinary symptoms associated with benign prostatic hyperplasia: analysis of international prostate symptom scores in 2 phase III clinical studies. Research and Reports in Urology. Volume 3. 1–5. 2 indexed citations

12.

Newman, Diane K., Philip M. Hanno, Roger R. Dmochowski, et al.. (2010). Effects of Oxybutynin Chloride Topical Gel on Health-Related Quality of Life in Adults with Overactive Bladder: A Randomized, Double-Blind, Placebo-Controlled Study. 2. 4 indexed citations

13.

Staskin, David, Roger R. Dmochowski, Peter K. Sand, et al.. (2009). Efficacy and Safety of Oxybutynin Chloride Topical Gel for Overactive Bladder: A Randomized, Double-Blind, Placebo Controlled, Multicenter Study. The Journal of Urology. 181(4). 1764–1772. 83 indexed citations

14.

Dmochowski, Roger R., David Staskin, Peter K. Sand, et al.. (2009). EFFICACY AND SAFETY OF OXYBUTYNIN CHLORIDE TOPICAL GEL IN WOMEN WITH OVERACTIVE BLADDER: A RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY. The Journal of Urology. 181(4). 589–589. 6 indexed citations

15.

Marks, Leonard S., Marc Gittelman, Lawrence A. Hill, Weining Volinn, & Gary Hoel. (2009). RAPID RESPONSE OF IRRITATIVE AND OBSTRUCTIVE URINARY SYMPTOMS OF BENIGN PROSTATIC HYPERPLASIA TO TREATMENT WITH SILODOSIN IN 2 RANDOMIZED STUDIES. The Journal of Urology. 181(4). 694–694. 1 indexed citations

16.

Thomas, Heather, et al.. (2009). PUK15 QUALITY OF LIFE IN A RANDOMIZED, DOUBLE-BLIND, PLACEBOCONTROLLED STUDY OF OXYBUTYNIN CHLORIDE TOPICAL GEL TREATMENT OF PATIENTS WITH OVERACTIVE BLADDER. Value in Health. 12(3). A200–A200. 1 indexed citations

17.

Marks, Leonard S., Marc Gittelman, Lawrence A. Hill, Weining Volinn, & Gary Hoel. (2009). Silodosin in the Treatment of the Signs and Symptoms of Benign Prostatic Hyperplasia: A 9-Month, Open-label Extension Study. Urology. 74(6). 1318–1322. 56 indexed citations

18.

Marks, Leonard S., Marc Gittelman, Lawrence A. Hill, Weining Volinn, & Gary Hoel. (2009). Rapid Efficacy of the Highly Selective α_1A-Adrenoceptor Antagonist Silodosin in Men With Signs and Symptoms of Benign Prostatic Hyperplasia: Pooled Results of 2 Phase 3 Studies. The Journal of Urology. 181(6). 2634–2640. 110 indexed citations

19.

Cartwright, Patrick C., et al.. (2009). Efficacy and Safety of Transdermal and Oral Oxybutynin in Children With Neurogenic Detrusor Overactivity. The Journal of Urology. 182(4). 1548–1554. 22 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact